NSE (Neuron Specific Enolase), Serum

Cancer

Report in 120Hrs

At Home

No Fasting Required

Details

Tumor marker.

₹4,070₹5,814

30% OFF

NSE (Neuron Specific Enolase) Serum - Comprehensive Test Guide

Why is it done?
- Test Purpose: NSE is a biomarker enzyme found primarily in neurons and neuroendocrine cells. This test measures serum levels of NSE to aid in the diagnosis and monitoring of neuroendocrine tumors, particularly small cell lung cancer (SCLC), and neurological conditions.
- Primary Indications: Suspected small cell lung cancer (SCLC), other neuroendocrine tumors, neuroblastoma, medullary thyroid carcinoma, carcinoid tumors, and neuroendocrine prostate cancer
- Clinical Applications: Diagnosis and staging of SCLC, treatment response monitoring, prognosis assessment, and surveillance for tumor recurrence
- Neurological Assessment: May be used as a marker in acute brain injury, neuronal damage assessment, and evaluation of paraneoplastic neurological syndromes
- Timing: Baseline testing prior to treatment, periodic monitoring during therapy (typically every 4-12 weeks), and follow-up surveillance during remission or recurrence assessment
Normal Range
- Reference Range: <16.3 ng/mL or <16.3 mcg/L (normal upper limit varies by laboratory; typical range: 0-12.5 ng/mL to 0-16.3 ng/mL)
- Units of Measurement: ng/mL (nanograms per milliliter) or mcg/L (micrograms per liter)
- Normal Result Interpretation: NSE within normal range suggests absence of neuroendocrine tumor or minimal neuronal damage; however, normal levels do not completely exclude malignancy
- Elevated Result Interpretation: NSE >16.3 ng/mL is considered elevated and warrants further investigation for neuroendocrine malignancy, neuronal injury, or other conditions affecting nervous tissue
- Clinical Cutoff Values: Mild elevation (16.3-25 ng/mL) may warrant clinical correlation; Moderate elevation (25-50 ng/mL) suggests possible malignancy; Significant elevation (>50 ng/mL) is highly suggestive of neuroendocrine malignancy
- Note: Reference ranges may vary between laboratories and testing methods; always refer to your specific laboratory's reference range provided with your test results
Interpretation
- Elevated NSE in SCLC Context: Highly elevated NSE (often >100 ng/mL) in patients with known or suspected SCLC indicates active tumor burden and serves as a prognostic marker. Values typically correlate with disease extent.
- Treatment Response Monitoring: Declining NSE levels during treatment suggest therapeutic response and tumor reduction. Stable or rising NSE despite treatment may indicate treatment failure or progressive disease requiring intervention adjustment.
- Prognostic Significance: Baseline NSE levels have prognostic value; patients with markedly elevated baseline NSE (>100 ng/mL) typically have poorer prognosis than those with lower levels. Serial NSE measurements provide better prognostic information than single values.
- Recurrence Detection: Rising NSE in patients in remission may precede radiological evidence of recurrence, making it valuable for early detection of disease progression. An increase of >20% from baseline may warrant further investigation.
- Factors Affecting Results: Hemolysis (red blood cell breakdown), smoking, exercise, renal insufficiency, hepatic disease, infection, inflammation, acute myocardial infarction, seizures, head trauma, and certain medications may elevate NSE. Recent physical trauma or medical procedures may also influence results.
- Sensitivity and Specificity: NSE has approximately 60-70% sensitivity for SCLC detection and 80-90% specificity. It is not diagnostic alone but serves as an adjunctive marker. Elevated NSE supports clinical suspicion when combined with imaging and histopathology.
- Negative Predictive Value: Normal NSE does not exclude SCLC or other neuroendocrine malignancies; approximately 30-40% of SCLC patients may have normal baseline NSE levels. Clinical evaluation and imaging remain essential regardless of NSE results.
Associated Organs
- Primary Organ Systems: Nervous system (central and peripheral neurons), neuroendocrine system, respiratory system (particularly lungs), and endocrine organs containing neuroendocrine cells
- Conditions Associated with Elevated NSE: Small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) with neuroendocrine differentiation, neuroblastoma, medullary thyroid cancer, carcinoid tumors, pheochromocytoma, paraneoplastic neurological syndromes, Merkel cell carcinoma, pancreatic neuroendocrine tumors
- Neurological Conditions: Acute brain injury, traumatic brain injury, epilepsy/seizures, stroke, hypoxic-ischemic encephalopathy, multiple sclerosis, Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions
- Other Acute Conditions: Acute myocardial infarction, cardiac arrest, severe infection/sepsis, acute liver injury, acute kidney injury, and inflammatory conditions affecting neuronal tissue
- Complications of Elevated NSE: Elevated NSE itself is not directly harmful but indicates underlying disease requiring urgent evaluation and treatment. Advanced neuroendocrine malignancies can lead to metastatic disease, organ dysfunction, paraneoplastic syndromes, and systemic complications.
- Organ-Specific Manifestations: Lung involvement: respiratory symptoms, hemoptysis, pleural effusion; Brain involvement: neurological symptoms, cerebral edema; Liver involvement: hepatic dysfunction, metastases; Bone involvement: pathological fractures, bone pain; Adrenal involvement: hormonal imbalances
Follow-up Tests
- Recommended Follow-up Imaging: Chest X-ray and CT scan of thorax with contrast (for lung lesions), CT abdomen/pelvis (for metastatic disease evaluation), MRI brain (if neurological symptoms present), PET-CT scan (to identify metastatic sites in SCLC)
- Complementary Tumor Markers: ProGRP (Pro-gastrin-releasing peptide) - highly specific for SCLC, Chromogranin A (CgA) - markers of neuroendocrine differentiation, Calcitonin (for medullary thyroid cancer), 5-HIAA (carcinoid syndrome), CEA and CYFRA 21-1 (non-small cell lung cancer markers)
- Histopathological Confirmation: Tissue biopsy with immunohistochemistry (IHC) staining for NSE, chromogranin, and synaptophysin to confirm neuroendocrine differentiation and establish definitive diagnosis
- Baseline Laboratory Assessment: Complete blood count (CBC), comprehensive metabolic panel (CMP), liver and renal function tests, lactate dehydrogenase (LDH), albumin levels to assess overall health and treatment tolerance
- Monitoring Frequency: Baseline NSE prior to treatment initiation, every 4-12 weeks during active therapy (aligned with treatment cycles), monthly during initial remission surveillance, every 3 months during long-term follow-up, more frequently if clinical changes occur
- Paraneoplastic Syndrome Workup: Testing for anti-neuronal antibodies (Anti-Hu, Anti-Yo, Anti-CRMP5), EEG if seizures present, CSF analysis if CNS involvement suspected, neurological consultation and testing as indicated
- Molecular and Genetic Testing: Next-generation sequencing (NGS) of tumor tissue, RB1 and TP53 mutations in SCLC, MEN1 mutations in pancreatic neuroendocrine tumors, for therapeutic targeting and prognostic stratification
- Neuroimaging Follow-up: Repeat imaging (CT/MRI) at baseline, post-treatment evaluation (6-8 weeks after therapy completion), and surveillance imaging every 3-6 months in remission or as clinically indicated
Fasting Required?
- Fasting Status: No, fasting is NOT required for NSE serum testing
- General Patient Preparation: Patient may eat and drink normally prior to blood draw. No special dietary restrictions are necessary.
- Timing Considerations: For optimal consistency, blood draw should preferably occur in the morning and at approximately the same time as previous draws if serial monitoring is planned. This minimizes diurnal variation.
- Activity Restrictions: Avoid strenuous exercise or intense physical activity for 24 hours prior to testing if possible, as vigorous activity can elevate NSE levels and affect results.
- Smoking Status: Cigarette smoking can elevate NSE levels. If possible, avoid smoking immediately before blood collection, though this is not an absolute contraindication.
- Medications: Continue all routine medications unless specifically instructed otherwise by your physician. Certain medications may affect results; inform the healthcare provider of all medications, supplements, and herbal products being taken.
- Recent Procedures or Trauma: Inform your healthcare provider if you have experienced recent head trauma, seizures, cardiac events, or invasive medical procedures, as these can elevate NSE levels and should be documented for result interpretation.
- Specimen Collection Instructions: A blood sample (serum) is collected via venipuncture into a tube without anticoagulant. Collect 5-10 mL into standard serum separator tube (SST). Avoid hemolysis by gentle tube handling, as damaged red blood cells release NSE and cause falsely elevated results.
- Sample Handling: Allow blood to clot for 30-60 minutes at room temperature, then centrifuge at 1000-2000 g for 10 minutes. Separate serum promptly. Store at 2-8°C if delayed processing or ship on ice to prevent degradation. Frozen storage at -20°C or lower is acceptable for long-term storage.

How our test process works!